150 related articles for article (PubMed ID: 8094598)
21. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical staining of Ki-67 using the monoclonal antibody Ki-s11 is a prognostic indicator for laryngeal squamous cell carcinoma.
Cordes C; Münzel AK; Rudolph P; Hoffmann M; Leuschner I; Gottschlich S
Anticancer Res; 2009 Apr; 29(4):1459-65. PubMed ID: 19414402
[TBL] [Abstract][Full Text] [Related]
24. A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node-negative primary breast carcinoma.
Imam SA; Chaiwun B; Wang MJ; Morris MM; Groshen SG; Neville AM; Torloni H; Cote RJ; Taylor CR
Anticancer Res; 1996; 16(5B):3043-8. PubMed ID: 8920764
[TBL] [Abstract][Full Text] [Related]
25. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of the cell cycle-associated monoclonal antibody Ki-S1 as a prognostic factor in primary invasive adenocarcinoma of the breast.
Morris ES; Elston CW; Bell JA; Galea M; Blamey RW; Ellis IO
J Pathol; 1995 May; 176(1):55-62. PubMed ID: 7616357
[TBL] [Abstract][Full Text] [Related]
27. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinomas: comparison with clinical and pathologic variables.
Frierson HF
Mod Pathol; 1993 May; 6(3):290-4. PubMed ID: 8102204
[TBL] [Abstract][Full Text] [Related]
29. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma.
Indinnimeo M; Cicchini C; Stazi A; Limiti MR; Ghini C; Mingazzini P; Vecchione A
J Exp Clin Cancer Res; 2000 Dec; 19(4):471-5. PubMed ID: 11277325
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
32. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
34. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry.
Parrado C; Falkmer UG; Höög A; Falkmer S; Ahrens O; Rius F; Grimelius L
Gen Diagn Pathol; 1996 Mar; 141(3-4):215-27. PubMed ID: 8705786
[TBL] [Abstract][Full Text] [Related]
35. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
36. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas.
Helin ML; Helle MJ; Helin HJ; Isola JJ
Arch Pathol Lab Med; 1989 Aug; 113(8):854-7. PubMed ID: 2667495
[TBL] [Abstract][Full Text] [Related]
37. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
39. Endothelial area as a prognostic indicator for invasive breast carcinoma.
Simpson JF; Ahn C; Battifora H; Esteban JM
Cancer; 1996 May; 77(10):2077-85. PubMed ID: 8640673
[TBL] [Abstract][Full Text] [Related]
40. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]